PROBIOTEC LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.83 AUD | -0.35% |
|
-0.35% | -2.41% |
| Feb. 27 | Probiotec Limited Declares Interim Dividend, Payable on 15 March 2024 | CI |
| Feb. 27 | Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 94.25 | 144.3 | 169.5 | 183 | 227.7 | 230.1 | - | - |
| Enterprise Value (EV) 1 | 94.25 | 149.3 | 191 | 209.2 | 260.6 | 298.4 | 316.2 | 304.8 |
| P/E ratio | 8.97 x | 21.2 x | 32.7 x | 13.2 x | 21.1 x | - | - | - |
| Yield | 2.23% | 2.33% | 2.31% | 2.44% | 2.32% | 2.58% | 2.58% | 3.18% |
| Capitalization / Revenue | 1.19 x | 1.35 x | 1.41 x | 1 x | 1.06 x | 0.97 x | 0.91 x | 0.87 x |
| EV / Revenue | 1.19 x | 1.39 x | 1.59 x | 1.15 x | 1.22 x | 1.25 x | 1.25 x | 1.15 x |
| EV / EBITDA | 9.63 x | 8.84 x | 8.84 x | 6.38 x | 7.39 x | 7.64 x | 6.91 x | 5.91 x |
| EV / FCF | - | 32.9 x | 9.47 x | - | 37.1 x | 25.5 x | 17.9 x | 16.7 x |
| FCF Yield | - | 3.04% | 10.6% | - | 2.7% | 3.92% | 5.6% | 5.97% |
| Price to Book | - | - | - | - | - | 2.47 x | 2.25 x | 2.05 x |
| Nbr of stocks (in thousands) | 60,035 | 74,779 | 78,463 | 81,323 | 81,323 | 81,323 | - | - |
| Reference price 2 | 1.570 | 1.930 | 2.160 | 2.250 | 2.800 | 2.830 | 2.830 | 2.830 |
| Announcement Date | 8/28/19 | 8/26/20 | 8/24/21 | 8/23/22 | 8/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 79.09 | 107.2 | 120.5 | 182.3 | 214 | 238.4 | 252.7 | 264.1 |
| EBITDA 1 | 9.791 | 16.9 | 21.6 | 32.77 | 35.25 | 39.05 | 45.79 | 51.57 |
| EBIT 1 | - | 12.6 | 15.2 | 22.95 | 23.94 | 24.95 | 29.1 | 33.15 |
| Operating Margin | - | 11.75% | 12.61% | 12.59% | 11.18% | 10.47% | 11.52% | 12.55% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | 6.4 | 5.1 | 13.71 | 11 | - | - | - |
| Net margin | - | 5.97% | 4.23% | 7.52% | 5.14% | - | - | - |
| EPS | 0.1750 | 0.0910 | 0.0660 | 0.1710 | 0.1330 | - | - | - |
| Free Cash Flow 1 | - | 4.544 | 20.18 | - | 7.024 | 11.7 | 17.7 | 18.2 |
| FCF margin | - | 4.24% | 16.74% | - | 3.28% | 4.91% | 7% | 6.89% |
| FCF Conversion (EBITDA) | - | 26.89% | 93.41% | - | 19.93% | 29.96% | 38.66% | 35.29% |
| FCF Conversion (Net income) | - | 71% | 395.64% | - | 63.85% | - | - | - |
| Dividend per Share 2 | 0.0350 | 0.0450 | 0.0500 | 0.0550 | 0.0650 | 0.0730 | 0.0730 | 0.0900 |
| Announcement Date | 8/28/19 | 8/26/20 | 8/24/21 | 8/23/22 | 8/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2023 S1 | 2023 S2 | 2024 S1 |
|---|---|---|---|
| Net sales 1 | 106.8 | 107.3 | 114 |
| EBITDA 1 | 17.23 | 18.02 | 17.24 |
| EBIT 1 | - | 12.49 | 8.127 |
| Operating Margin | - | 11.64% | 7.13% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | 0.0662 | - | - |
| Dividend per Share 2 | 0.0300 | 0.0350 | 0.0350 |
| Announcement Date | 2/23/23 | 8/24/23 | 2/27/24 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4.99 | 21.6 | 26.3 | 32.9 | 68.3 | 86.1 | 74.6 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.2955 x | 0.9978 x | 0.8014 x | 0.9335 x | 1.748 x | 1.88 x | 1.447 x |
| Free Cash Flow 1 | - | 4.54 | 20.2 | - | 7.02 | 11.7 | 17.7 | 18.2 |
| ROE (net income / shareholders' equity) | - | 11.6% | 14.2% | 18.2% | 15.6% | - | - | - |
| ROA (Net income/ Total Assets) | - | 5.32% | 5.01% | 5.73% | 5.48% | 7.94% | 8.17% | 0.08% |
| Assets | - | 120.2 | 101.8 | 239.1 | 200.7 | - | - | - |
| Book Value Per Share 2 | - | - | - | - | - | 1.150 | 1.260 | 1.380 |
| Cash Flow per Share 2 | - | - | - | - | 0.2100 | 0.2700 | 0.3700 | 0.4300 |
| Capex 1 | 12.5 | 5.63 | 4.19 | 6.93 | 10.1 | 10.1 | 12.3 | 17.1 |
| Capex / Sales | 15.82% | 5.25% | 3.48% | 3.8% | 4.74% | 4.23% | 4.86% | 6.47% |
| Announcement Date | 8/28/19 | 8/26/20 | 8/24/21 | 8/23/22 | 8/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.83
AUD
Average target price
3
AUD
Spread / Average Target
+6.01%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.41% | 150M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PBP Stock
- Financials Probiotec Limited
